COMPASS Pathways: Q3 net loss $18.4M ($0.43/share); Phase 3 program on track for 2022 start

COMPASS Pathways plc

2022-Q3 EPS reported -$1.43

Net loss of $18.4M in Q3 2022 vs. $15.8M in Q3 2021; cash $173.1M as of Sept 30, 2022.
Phase 3 pivotal program for COMP360 in treatment-resistant depression on track to start in 2022.
Phase 2b trial data published in The New England Journal of Medicine.
Phase 2 trials ongoing in anorexia nervosa and PTSD; investigator-led study in autism launched.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COMPASS Pathways plc reported three months and nine months ended September 30, 2022 results: net income Net loss for the three months ended 30 September 2022 was $18.4 million, or $0.43 loss per share, EPS $0.43 loss per share.

Period: three months and nine months ended September 30, 2022
Net income: Net loss for the three months ended 30 September 2022 was $18.4 million, or $0.43 loss per share
EPS: $0.43 loss per share
Result: reported results

Exact text from the filing

Net loss for the three months ended 30 September 2022 was $18.4 million, or $0.43 loss per share (including non-cash share-based compensation expense of $3.5 million), compared with $15.8 million or $0.38 loss per share, during the same period in 2021

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001816590-22-000117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.